Recombinant Human SMARCA4, GST-tagged

• Cat.No.: SMARCA4-1910H
• Product Overview: Recombinant Human SMARCA4 (1448-1575 aa) was expressed in E. coli.

Specification

• Description: The acetylation of histone lysine residues plays a crucial role in the epigenetic regulation of gene transcription. A bromodomain is a protein domain that recognizes acetylated lysine residues such as those on the N-terminal tails of histones. This recognition is often a prerequisite for protein-histone association and chromatin remodeling. These domains function in the linking of protein complexes to acetylated nucleosomes, thereby controlling chromatin structure and gene expression. Thus, bromodomains serve as "readers" of histone acetylation marks regulating the transcription of target promoters. BRG1 is a member of the SWI/SNF protein family, which forms part of a large ATP-dependent chromatin remodeling complex. This complex is required for transcriptional activation of genes normally repressed by chromatin. BRG1 is mutated in many cancer cell lines, such as breast, prostate, lung, pancreas and colon. Further, BRG1 has an important role as a tumor suppressor. This protein can be used for the study of bromodomain binding assays, screening inhibitors, and selectivity profiling.
• Source: E. coli
• Species: Human
• Tag: GST
• Appearance: Liquid
• Form: 50 mM Tris, pH 7.5, containing 500 mM sodium chloride, 5% glycerol, and 5 mM β-mercaptoethanol.
• Molecular Mass: 41.8 kDa (1448-1575 aa + GST Tag)
• Protein length: 1448-1575 aa
• Purity: ≥95% by SDS-PAGE
• Usage: For Research Use Only! Not For Use in Humans.
• Storage: Store at -80°C. Avoid repeated freeze and thaw cycles. Stable for 1 year.

Gene Information

• Gene Name: SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 [ Homo sapiens(human) ]
• Official Symbol: SMARCA4
• Synonyms: SMARCA4; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4; BRG1; SNF2; SWI2; MRD16; RTPS2; BAF190; SNF2L4; SNF2LB; hSNF2b; BAF190A; transcription activator BRG1; SNF2-beta; SNF2-like 4; protein BRG-1; nuclear protein GRB1; brahma protein-like 1; BRM/SWI2-related gene 1; homeotic gene regulator; protein brahma homolog 1; BRG1-associated factor 190A; sucrose nonfermenting-like 4; ATP-dependent helicase SMARCA4; mitotic growth and transcription activator; global transcription activator homologous sequence
• Gene ID: 6597
• mRNA Refseq: NM_003072
• Protein Refseq: NP_003063
• MIM: 603254
• UniProt ID: P51532
• Chromosome Location: 19p13.2
• Pathway: Direct p53 effectors; Glucocorticoid receptor regulatory network; Integrated Breast Cancer Pathway
• Function: ATP binding; DNA binding; DNA-dependent ATPase activity; RNA polymerase II transcription coactivator activity

Reviews

02/18/2023

The SMARCA4 protein offers exceptional quality that meets the rigorous demands of experimental research.

11/01/2018

It exhibits exceptional performance in ELISA assays, making it an excellent choice for researchers studying angiopoietins, angiogenesis, or vascular biology.

10/30/2016

Its purity, consistency, and reliable performance make it a top choice for a wide range of applications.

Q&As

Can epigenetic therapies target SMARCA4 alterations?

Epigenetic therapies that modulate gene expression could indirectly affect SMARCA4-altered cancers, though specific targeting remains a challenge.

Are there diagnostic tests for SMARCA4 mutations?

Yes, there are genetic tests available to identify SMARCA4 mutations in tumors, aiding in prognosis and treatment decisions.

Are there ongoing clinical trials focusing on SMARCA4 alterations?

Yes, there are clinical trials exploring new treatment strategies for SMARCA4-altered cancers, aiming to improve patient outcomes.

Is SMARCA4 solely associated with cancer?

No, SMARCA4's functions extend beyond cancer and have implications in various biological processes, including development and differentiation.

How can SMARCA4 mutations influence patient prognosis?

Patients with SMARCA4 mutations in their tumors often face a poorer prognosis, which necessitates tailored treatment approaches.